CAPR — Capricor Therapeutics Inc
NASDAQ · Healthcare · Biotechnology
$10.09
+$0.08 (+0.80%)
Capricor Therapeutics Inc (CAPR) is a biotechnology company listed on NASDAQ. It is led by Linda Marbán Ph.D., based in 10865 Road to the Cure, San Diego, CA, United States, 92121, with about 231 employees. Capricor Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of transformative cell and exosome-based therapeutics for treating duchenne muscular dystrophy (DMD) and other diseases with unmet medical needs in the United States. Its lead product candidate is the Deramiocel, an allogeneic cardiosphere-derived cells, which is in phase 3 clinical trial for the treatment of DMD. The company also develops Exosome protein-based vaccine, which is in preclinical trial to treat SARS-CoV-2; StealthX Exosome Platform, and exosome platform program consists of engineered exosomes for vaccine and therapeutic development and is in preclinical trial. In addition, it engages in developing StealthX, an engineered exosome-based vaccine candidate, under phase 1 clinical study for a range of therapeutic applications, including targeted RNA, protein, and small molecule therapeutics to treat or prevent a variety of diseases; It has license agreement with Johns Hopkins University, University of Rome License, and Cedars-Sinai Medical Center to develop and commercialize licensed products and licensed services under the licensed patent rights in all fields and a nonexclusive right to the know-how; Cell Line License Agreement with Life Technologies for the development of exosomes platform. The company was founded in 2005 and is headquartered in San Diego, California.
Net income was -$74.9M. CAPR currently screens at market cap $1.62B.
Use this CAPR page for company research — sector, financials, and the latest filing takeaway — not a live tape. The session quote (last, range, volume) lives on the CAPR quote page. Cached 10-K, 10-Q, 8-K, and Form 4 exhibits are on the CAPR SEC filings page. Lician reads the product cache first so this HTML stays unique to Capricor Therapeutics Inc even when a live quote feed is slow.
About Capricor Therapeutics Inc
Capricor Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of transformative cell and exosome-based therapeutics for treating duchenne muscular dystrophy (DMD) and other diseases with unmet medical needs in the United States. Its lead product candidate is the Deramiocel, an allogeneic cardiosphere-derived cells, which is in phase 3 clinical trial for the treatment of DMD. The company also develops Exosome protein-based vaccine, which is in preclinical trial to treat SARS-CoV-2; StealthX Exosome Platform, and exosome platform program consists of engineered exosomes for vaccine and therapeutic development and is in preclinical trial. In addition, it engages in developing StealthX, an engineered exosome-based vaccine candidate, under phase 1 clinical study for a range of therapeutic applications, including targeted RNA, protein, and small molecule therapeutics to treat or prevent a variety of diseases; It has license agreement with Johns Hopkins University, University of Rome License, and Cedars-Sinai Medical Center to develop and commercialize licensed products and licensed services under the licensed patent rights in all fields and a nonexclusive right to the know-how; Cell Line License Agreement with Life Technologies for the development of exosomes platform. The company was founded in 2005 and is headquartered in San Diego, California.
CAPR Key Statistics
Market Cap
$1.62B
Volume
17.53M
Previous Close
$6.80
Day Range
$7.25 – $8.60
P/B Ratio
5.42
EPS
-$1.15
Revenue
$22.27M
Net Income
-$40.47M
Gross Profit
$0.00
Free Cash Flow
$0.00
Revenue Growth
-11.5%
Profit Margin
-181.7%
Employees
231
CAPR Financials
Annual income statement in USD. Latest reported periods first.
| Line | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|
| Revenue | $22.27M | $25.18M | $2.55M | $244.90K |
| Cost of Revenue | $0.00 | $0.00 | $0.00 | $0.00 |
| Gross Profit | $0.00 | $0.00 | $0.00 | $0.00 |
| Operating Income | $0.00 | $0.00 | $0.00 | $0.00 |
| Net Income | -$40.47M | -$22.29M | -$29.02M | -$20.02M |
| EPS (Diluted) | -$1.15 | -$0.83 | -$1.18 | -$0.87 |
Total Assets
$170.48M
Total Debt
$0.00
Shareholders' Equity
$0.00
Cash & Equivalents
$11.29M
Operating Cash Flow
-$40.00M
Free Cash Flow
$0.00
Capricor Therapeutics Inc Company Information
- Co-Founder, President, CEO & Director
- Linda Marbán Ph.D.
- Headquarters
- 10865 Road to the Cure, San Diego, CA, United States, 92121
- Website
- www.capricor.com
- Phone
- 858 727 1755
- IPO / Founded
- 2007-02-13
- Sector
- Healthcare
- Industry
- Biotechnology